Pharm Res. 2013 Nov;30(11):2931-9. doi: 10.1007/s11095-013-1168-3.
To determine the effect of PepT1 on the absorption and disposition of cefadroxil, including the potential for saturable intestinal uptake, after escalating oral doses of drug.
The absorption and disposition kinetics of [3H]cefadroxil were determined in wild-type and PepT1 knockout mice after 44.5, 89.1, 178, and 356 nmol/g oral doses of drug. The pharmacokinetics of [3H]cefadroxil were also determined in both genotypes after 44.5 nmol/g intravenous bolus doses.
PepT1 deletion reduced the area under the plasma concentration-time profile (AUC0-120) of cefadroxil by 10-fold, the maximum plasma concentration (Cmax) by 17.5-fold, and increased the time to reach a maximum plasma concentration (Tmax) by 3-fold. There was no evidence of nonlinear intestinal absorption since AUC0-120 and Cmax values changed in a dose-proportional manner. Moreover, the pharmacokinetics of cefadroxil were not different between genotypes after intravenous bolus doses, indicating that PepT1 did not affect drug disposition. Finally, no differences were observed in the peripheral tissue distribution of cefadroxil (i.e., outside gastrointestinal tract) once these tissues were corrected for differences in perfusing blood concentrations.
The findings demonstrate convincingly the critical role of intestinal PepT1 in both the rate and extent of oral administration for cefadroxil and potentially other aminocephalosporin drugs.
确定 PepT1 对头孢羟氨苄吸收和分布的影响,包括药物递增口服剂量后肠道摄取的潜在饱和性。
在野生型和 PepT1 敲除小鼠中,分别给予[3H]头孢羟氨苄 44.5、89.1、178 和 356 nmol/g 口服剂量后,确定[3H]头孢羟氨苄的吸收和处置动力学。在两种基因型中,还在给予 44.5 nmol/g 静脉推注剂量后确定[3H]头孢羟氨苄的药代动力学。
PepT1 缺失使头孢羟氨苄的血浆浓度-时间曲线下面积(AUC0-120)减少了 10 倍,最大血浆浓度(Cmax)减少了 17.5 倍,达到最大血浆浓度的时间(Tmax)增加了 3 倍。由于 AUC0-120 和 Cmax 值呈剂量比例变化,因此没有证据表明存在非线性肠道吸收。此外,静脉推注剂量后两种基因型的头孢羟氨苄药代动力学无差异,表明 PepT1 不影响药物处置。最后,一旦校正了灌注血浓度的差异,头孢羟氨苄在周围组织(即胃肠道外)的分布无差异。
这些发现令人信服地证明了肠道 PepT1 在头孢羟氨苄和潜在其他氨基头孢菌素类药物的口服给药速度和程度中具有关键作用。